BELLUS Health (BELLUS Health) ROCE % : -26.28% (As of Mar. 2023)

View and export this data going back to 2000. Start your Free Trial

What is BELLUS Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BELLUS Health's annualized ROCE % for the quarter that ended in Mar. 2023 was -26.28%.

BELLUS Health ROCE % Historical Data

The historical data trend for BELLUS Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BELLUS Health ROCE % Chart

BELLUS Health Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-22.99

-41.29

-26.85

-32.43

-22.19

BELLUS Health Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROCE %	Get a 7-Day Free Trial															-19.98	-27.49	-29.44	-18.23	-26.28

BELLUS Health ROCE % Calculation

BELLUS Health's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-75.942	/	( ( (309.595 - 16.949)	+	(407.82 - 15.876) )	/ 2 )
	=	-75.942	/	( (292.646	+	391.944)	/ 2 )
	=	-75.942	/	342.295
	=	-22.19 %

BELLUS Health's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	-100.084	/	( ( (407.82 - 15.876)	+	(379.543 - 9.805) )	/ 2 )
	=	-100.084	/	( ( 391.944	+	369.738 )	/ 2 )
	=	-100.084	/	380.841
	=	-26.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

BELLUS Health (NAS:BLU) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BELLUS Health ROCE % Related Terms

Thank you for viewing the detailed overview of BELLUS Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BELLUS Health (BELLUS Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BELLUS Health Inc (NAS:BLU) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Armand-Frappier Boulevard, Laval, QC, CAN, H7V 4A7

Website

http://www.bellushealth.com

BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.